GlassScriptPhysician profile
Lance S Patton
NPI 1104822816
$3,023.57
in general payments reported to CMS, 2019-2025
34 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $92.40 · 2021: $189 · 2022: $449 · 2023: $592 · 2024: $810 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Education: $12.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.51 |
| Education | $12.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $680.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $450.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $225.12 | 2022-2025 | |
| Pfizer INC. | $219.90 | 2019-2025 | |
| Philips North America LLC | $196.26 | 2019-2024 | (7999) Src Und |
| Lilly USA, LLC | $115.96 | 2022-2024 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $109.31 | 2021-2025 | Gvoke Hypopen |
| Heartflow, INC. | $93.39 | 2025 | |
| Amgen INC. | $77.58 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.43 | 2022-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $67.40 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.36 | 2023-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $55.92 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $54.07 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.84 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2024-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $41.54 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.10 | 2023 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Resmed Corp | $37.10 | 2023-2024 | |
| Axsome Therapeutics, INC. | $24.94 | 2025 | Sunosi |
| Boston Scientific Corporation | $24.83 | 2025 | General - Erectile Dysfunction |
| Fisher & Paykel Healthcare INC | $24.50 | 2024 | Fisher & Paykel Healthcare |
| Jazz Pharmaceuticals INC. | $24.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.15 | 2024 | Rexulti |
| Corcept Therapeutics | $20.25 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $20.23 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $18.59 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $18.56 | 2025 | |
| Exact Sciences Corporation | $17.26 | 2023 | Cologuard Collection Kit |
| Itamar Medical INC | $16.30 | 2025 | Watchpatone |
| Mylan Specialty L.P. | $13.92 | 2023 | Yupelri |
| Astellas Pharma US INC | $13.78 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.